How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%Zacks Investment Research • 08/29/24
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNCBusiness Wire • 08/15/24
Shareholder Alert: Ademi LLP investigates whether Revance Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersPRNewsWire • 08/15/24
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNCGlobeNewsWire • 08/13/24
Can Revance Therapeutics (RVNC) Climb 98.64% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/13/24
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc.PRNewsWire • 08/12/24
RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 08/12/24
RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown LaboratoriesGlobeNewsWire • 08/12/24
Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/24
Revance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateBusiness Wire • 08/08/24
Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024Business Wire • 08/01/24
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/24/24
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateBusiness Wire • 05/09/24